Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
종목 코드 DARE
회사 이름Dare Bioscience Inc
상장일Apr 10, 2014
CEOJohnson (Sabrina Martucci)
직원 수21
유형Ordinary Share
회계 연도 종료Apr 10
주소3655 Nobel Dr Ste 260
도시SAN DIEGO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92122-1050
전화18589267655
웹사이트https://www.darebioscience.com/
종목 코드 DARE
상장일Apr 10, 2014
CEOJohnson (Sabrina Martucci)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음